Evidence map›Paper›PMID 34365537›Full record

ArticleDigestive diseases and sciences2022

Bile Acid Malabsorption in Patients with Neuroendocrine Tumors.

Lehar Khanna, Thorvardur R Halfdanarson, Mohamad B Sonbol, Rachel Eiring, Teresa Prond, Michael Camilleri

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Digestive diseases and sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Review
  3. New Developments in Bile Acid Diarrhea.Gastroenterology & hepatology · 2023
    Article
  4. BAM ≢ BAD.Digestive diseases and sciences · 2022
    Article
  5. Bile acid detergency: permeability, inflammation, and effects of sulfation.American journal of physiology. Gastrointestinal and liver physiology · 2022
    Review
  6. Bile Acid Diarrhea in Adults and Adolescents.Neurogastroenterology and motility · 2022
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Lehar KhannaClinical Enteric Neuroscience Translational and Epidemiological Research (C.E.N.T.E.R.), Division of Gastroenterology and Hepatology, Mayo Clinic, 200 First St. S.W., Rochester, MN, 55905, USA.
Thorvardur R HalfdanarsonDivision of Medical Oncology, Mayo Clinic, 200 First St. S.W., Rochester, MN, 55905, USA.
Mohamad B SonbolDivision of Medical Oncology, Mayo Clinic, 200 First St. S.W., Rochester, MN, 55905, USA.
Rachel EiringDivision of Medical Oncology, Mayo Clinic, 200 First St. S.W., Rochester, MN, 55905, USA.
Teresa ProndDivision of Medical Oncology, Mayo Clinic, 200 First St. S.W., Rochester, MN, 55905, USA.
Michael CamilleriClinical Enteric Neuroscience Translational and Epidemiological Research (C.E.N.T.E.R.), Division of Gastroenterology and Hepatology, Mayo Clinic, 200 First St. S.W., Rochester, MN, 55905, USA. camilleri.michael@mayo.edu.ORCID 0000-0001-6472-7514
Mayo Clinic · US

Funding

Genetic Control and Ileo-Colonic Mucosal Expression of Bile Acid-Related Mechanisms in Irritable Bowel Syndrome-DiarrheaR01DK115950 · NIDDK · MAYO CLINIC ROCHESTER · PI CAMILLERI, MICHAEL L. · 2018 to 2021
$1.8M
NIDDK NIH HHS R01 DK115950
6 · The paper itself

Abstract

backgroundChronic diarrhea in patients with neuroendocrine tumors (NET) may be caused by bioactive products of NET, bile acid malabsorption (BAM), ileal resection (IR) or steatorrhea.

aimTo quantitate BA and fat malabsorption in NET with diarrhea.

methodsPart of evaluation in medical oncology clinical practice, 67 patients [42F, 25 M; median age 64.0 y (17.0 IQR)] with well-differentiated NET and diarrhea underwent clinically indicated measurements of 48-h fecal BA [(FBA), fecal weight (normal < 400 g/48 h), fecal fat (normal < 7 g/day) in n = 52] and fasting serum 7αC4 (marker of hepatic BA synthesis, n = 30) between 01/2018 and 11/2020. IR had been performed in 45 patients. BAM diagnosis was based on FBA criteria: elevated total FBA (> 2337 µmol/48 h) or > 10% primary FBA or combination > 4% primary FBA plus > 1000 µmol total FBA/48 h. We also measured fecal elastase (for pancreatic insufficiency) in 13 patients.

resultsBAM was present in 48/52 (92%) patients with NET. There were significant correlations between total FBA and 48-h fecal weight (R

conclusionA majority of patients with NET and diarrhea had BAM, even with < 25 cm or no IR.

Indexed as

Malabsorption SyndromesNeuroendocrine TumorsSteatorrheaBile Acids and SaltsDiarrheaFecesHumansMiddle AgedBile Acids and SaltsPancreasPrimarySomatostatinSteatorrhea

Identifiers

PMID34365537
PMCPMC8818805
OpenAlexW3189409648

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.